Personalized treatment for atrial fibrillation based on genetics
Genotype-guided therapy for atrial fibrillation
This study is looking at how your genes might affect how well antiarrhythmic drugs work for treating atrial fibrillation, so we can find out which patients will benefit the most from these medications and make treatment more effective and safer for you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-10902019 on NIH RePORTER |
What this research studies
This research investigates how genetic variations can influence the effectiveness of antiarrhythmic drugs in treating atrial fibrillation (AF). By focusing on a specific genetic marker, the study aims to identify which patients are more likely to benefit from these medications, potentially reducing adverse effects and improving treatment outcomes. Patients with symptomatic AF will be assessed to determine their genetic profile, which will guide personalized therapy decisions. The goal is to enhance the predictability of treatment responses and minimize the trial-and-error approach currently used in managing AF.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with symptomatic atrial fibrillation who are considering antiarrhythmic drug therapy.
Not a fit: Patients without atrial fibrillation or those who are not candidates for antiarrhythmic drugs may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients with atrial fibrillation.
How similar studies have performed: Previous research has shown promise in using genetic markers to guide treatment decisions in other conditions, suggesting potential success for this approach in atrial fibrillation.
Where this research is happening
Chicago, UNITED STATES
- University of Illinois at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Darbar, Dawood — University of Illinois at Chicago
- Study coordinator: Darbar, Dawood
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.